[Collection of cases in relation to clinical trials of fluconazole in Germany].
Fluconazole is a new antifungal agent from the class of triazoles for systemic treatment of fungal infections caused by Candida or Cryptococcus. From September 1988 to June 1990, fluconazole has been made available free of charge in a clinical trial for the treatment of patients who failed to respond to conventional therapy or in whom conventional therapy was limited due to side effects etc. (compassionate usage program). Overall, 1,188 patients were entered including 79 with cryptococcal meningitis, 665 with life-threatening and 444 with non-life-threatening candidosis. The following results were found in an interim evaluation of 254 cases: The therapeutic success (cure and improvement) was 43% in patients with cryptococcal meningitis, 54% in life-threatening candidosis and 67% in non-life-threatening candidosis.
Krisch
H
H
Klinische Forschung Pfizer, Karlsruhe.
Sarnow
E
E
D000328:Adult; D002177:Candidiasis / Q000188:drug therapy*; D003453:Cryptococcosis / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008581:Meningitis / Q000188:drug therapy*
D015725:Fluconazole
Sammlung von Kasuistiken im Rahmen der klinischen Erprobung von Fluconazol in Deutschland.